Seventure Partners appeared to be the VC, which was created in 1997. The company was established in Europe in France. The main office of represented VC is situated in the Paris.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Seventure Partners, startups are often financed by Sofinnova Partners, Societe Generale Asset Management, Alven Capital. The meaningful sponsors for the fund in investment in the same round are XAnge, Sofinnova Partners, Omnes Capital. In the next rounds fund is usually obtained by Bpifrance, EASME - EU Executive Agency for SMEs, Auriga Partners.
For fund there is a match between the location of its establishment and the land of its numerous investments - France. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Among the most popular fund investment industries, there are Health Care, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight DayTwo, Launchmetrics, BIOMx.
The fund is generally included in 7-12 deals every year. The increased amount of exits for fund were in 2016. The average startup value when the investment from Seventure Partners is 10-50 millions dollars. The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. Deals in the range of 5 - 10 millions dollars are the general things for fund. Speaking about the real fund results, this VC is 16 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Seventure Partners performs on 2 percentage points less the average number of lead investments.
We also calculated 12 valuable employees in our database.
|$10M||11 Oct 2022||Copenhagen, Hovedstaden, Denmark|
|$14M||14 Sep 2022||Paris, Ile-de-France, France|
|$5M||12 Jul 2022||Berlin, Berlin, Germany|
|$46M||10 May 2022||France, Grand Est, France|
|$70M||03 May 2022||Munich, Bavaria, Germany|
|$12M||13 Apr 2022||Davis, California, United States|
|$5M||29 Mar 2022||Bretagne, Brittany, France|
|$4M||15 Mar 2022||Tours, Centre-Loire Valley, France|
|$68M||07 Feb 2022||Cambridge, England, United Kingdom|
– Dopavision, a Berlin, Germany-based company focused on development of digital therapeutics, raised €12M in Series A funding.
– The round was led by Seventure Partners with participation from Novartis Pharmaceuticals, Boehringer Ingelheim Venture Fund and Ababax Health.
– The new investment will be used for the clinical development of MyopiaX, its lead product in childhood myopia, activities to provide innovative digital treatments for children leveraging games, educational or cognitive training applications, and potentially broaden its pipeline to new indications.
– Foodsmart, the personalized telenutrition and foodcare leader, has announced a Series C funding of more than $25m.
– The round was led by Advocate Aurora Enterprises, a newly launched subsidiary of Advocate Aurora Health, one of the largest health systems in the United States.
– Foodsmart’s Series C round also included participation from Mayfield Fund, Seventure Partners (Health for Life Capital), New Ground Ventures, Benefitfocus Founder Shawn Jenkins, Classpass CEO Fritz Lanman and former Darden Restaurants CEO Clarence Otis.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.